Symposium on neurosciencesGuillain-Barré Syndrome
Section snippets
The Eponym and 100 Years of Clinical Advances
George Guillain (ghee-lain6) was a student of Pierre Marie, the recipient of the Charcot chair at the Salpêtrière (Figure 1, A). Guillain was one of his most prolific pupils and would become his successor in 1925. In 1916, George Guillain,1 Jean-Alexandre Barré, and André Strohl described acute and progressive limb weakness causing major difficulty in 2 soldiers they examined in an army hospital during the battle of the Somme (northern France, World War I). The key features were (1) the
Pathogenesis
Multiple antecedent and potentially triggering events have been reported.22 The association with infections is established in not only C jejuni but also cytomegalovirus, Epstein-Barr virus, influenza A, Mycoplasma pneumoniae, Haemophilus influenzae, hepatitis (A, B, and E). and Zika virus.23, 24, 25, 26 The risk of GBS from influenza vaccine varies from 3 cases per million to as low as zero.27, 28, 29 Surgery may predispose patients to GBS (more likely in patients with prior malignant or
Clinical Presentation
The diagnosis of GBS is fairly typical, and the differential diagnosis is narrow. Symptoms and signs usually progress within 1 to 2 weeks. Severe back pain and distal limb paresthesias with a “tight band” feeling are common presenting signs, and the paresthesias gradually scatter over the limbs and move proximally. Although tingling is often the presenting symptom, sensory modalities remain normal to mildly impaired. Weakness begins in the more proximal muscles, causing difficulty with climbing
Mimicking Disorders
Very few disorders mimic GBS because their symptoms do not ascend, are not rapid, and are not postinfectious. The more likely candidates are presented in Table 1.59 Other disorders to consider are acute heavy metal intoxication, severe rhabdomyolysis (eg, rhabdomyolysis due to statin use), severe hypokalemia or hypophosphatemia, and intermittent porphyria. Guillain-Barré syndrome can be a first manifestation of chronic inflammatory demyelinating polyneuropathy, which typically worsens over 2
Laboratory Tests
Cerebrospinal fluid analysis typically reveals high protein levels with a normal white blood cell count (the classic albuminocytologic dissociation). Although unusual, more than 10 white blood cells per high-power field may be seen but is more common in associated disorders such as Lyme disease, sarcoidosis, and AIDS. Because CSF can include a normal cell count and normal protein level in weak patients early in presentation, its usefulness is questionable. Lumbar puncture may be more
General Management
Many patients with GBS become bedbound, and this immobilization requires expert nursing care. Skin, eye, and mouth care is crucial to the comfort of quadriplegic patients.
ICU Management
The management of patients with GBS is difficult because of its unpredictable course, potential for rapid deterioration, and high chances for respiratory failure. Any patient with worsening weakness on initial evaluation or presentation requires admission and observation in an ICU (Figure 4). However, only 1 in 3 patients will experience deterioration severe enough to mandate further or prolonged close monitoring and possibly endotracheal intubation.22, 72
Respiratory failure and GBS can be
Outcome
Severe manifestations of GBS admitted to the neurosciences intensive care unit involves long-term respiratory care, management of dysautonomia (wide blood pressure swings and cardiac arrhythmias) and management of major systemic complications. Although supposedly benign when described initially, far more serious and critical appearences became recognized.81 Several patients accounts of the experience have been published varying from titles such “My worst nightmare” (Byron Comp) to “Happily ever
Precautions
Questions about vaccinations after GBS are very common but difficult to definitively answer because there might be some risk with any type of vaccination. No cases of GBS or recurrent GBS after any type of vaccination were found in a Kaiser Permanente study.84 The benefit of influenza vaccination is great and in particular in elderly patients with pulmonary disease. The decision to proceed with vaccination is at the discretion of the physician in discussion of pro's and con's with the patient.
Future Directions and Immediate Challenges
Although GBS was initially described 100 years ago, its recent occurrence in association with the Zika virus emphasizes the importance of ongoing study of this disorder.87 In those affected, the most common presentation was that of acute motor axonal neuropathy, with 19% having novel autoantibodies to the glycolipid GA1. The virus is spread by mosquito-borne infection and sexual transmission and will most likely spread to the Americas. Epidemiological research to identify and control outbreaks
Conclusion
Guillain-Barré syndrome is a well-recognized, acute, disabling neurologic illness. Management is supportive with immunomodulating therapy but may involve prolonged intensive care and long-term neurorehabilitation. Without a full understanding of its pathophysiology, it will be difficult to find a treatment that dramatically hastens the slow recovery trajectory. Guillain-Barré syndrome can profoundly affect a patient's life and family because it may take years to resolve completely. Patients
References (89)
- et al.
Influenza vaccine, Guillain-Barré syndrome, and chasing zero
Vaccine
(2012) - et al.
Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis
Lancet
(2013) Autonomic dysfunction in the Guillain-Barré syndrome
Am J Med
(1971)- et al.
The mechanism of hypertension in the Guillain-Barré syndrome
Am J Med
(1967) - et al.
Guillain-Barré syndrome
Lancet
(2005) - et al.
Treatment of acute polyneuropathy by plasma exchange
Lancet
(1978) - et al.
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
Lancet Neurol
(2008) - et al.
Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial
Lancet
(2004) - et al.
Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study
Lancet
(2016) - et al.
Sur un syndrome de radiculonévrite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire: remarques sur les caractères cliniques et graphiques des reflexes tendineux
Bull Memoires Soc Med Hopitaux Paris
(1916)
GBS100: Celebrating a century of progress in Guillain-Barré syndrome
Zika virus: the latest newcomer
Front Microbiol
Zika virus as a cause of neurologic disorders
N Engl J Med
Pronunciation of Dr Georges Guillain's name
JAMA
Note sur la paralysie ascendante aiguē
Gaz Hebd Med
The Guillain-Barre syndrome
The Landry-Guillain-Barré syndrome: a clinicopathologic report of 50 fatal cases and a critique of the literature
Medicine (Baltimore)
The Landry-Guillain-Barr'e-Strohl syndrome or polyradiculoneuropathy: historical review, report on 97 patients, and present concepts
Mayo Clin Proc
Swine influenza vaccine and Guillain-Barré syndrome: epidemic or artifact?
Arch Neurol
An acute axonal form of Guillain-Barré polyneuropathy
Brain
Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China
Ann Neurol
Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies
Brain
Guillain-Barré syndrome in northern China: the spectrum of neuropathological changes in clinically defined cases
Brain
Pathology of the motor-sensory axonal Guillain-Barré syndrome
Ann Neurol
Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis
Neurology
Plasmapheresis and acute Guillain-Barré syndrome
Neurology
A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome
N Engl J Med
Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome
Lancet
Practice parameter: immunotherapy for Guillain-Barre syndrome; report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurology
Guillain-Barré Syndrome
The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study
Neurology
The risk of Guillain-Barré syndrome following infection with
Campylobacter jejuni Epidemiol Infect
Haemophilus influenzae infection and Guillain-Barré syndrome
Brain
Campylobacter jejuni infection and Guillain-Barré syndrome
N Engl J Med
The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines
N Engl J Med
Molecular mimicry and Guillain-Barré syndrome
Brain Nerve
Axonal variant of Guillain-Barré syndrome associated with Campylobacter infection in Bangladesh
Neurology
Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan
Ann Neurol
Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome
Proc Natl Acad Sci U S A
A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure
J Exp Med
Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome
Ann Neurol
An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia)
N Engl J Med
Cited by (132)
Approach to diagnosis, evaluation, and treatment of generalized and nonlocal dysesthesia: A review
2023, Journal of the American Academy of DermatologyIncidence of Guillain-Barré syndrome in the world between 1985 and 2020: A systematic review
2023, Global EpidemiologyGuillain–Barre Syndrome in Children and Adolescents
2023, Advances in PediatricsGuillain-Barré Syndrome associated with SARS-CoV-2 infection in Nepal: A case report
2022, Annals of Medicine and SurgeryNeurosurgical Mimics
2022, Neurologic ClinicsCitation Excerpt :The average symptom onset is within 2 weeks of infection, and usually manifest with distal symmetric ascending lower limb weakness and areflexia; however, it can present initially with proximal lower limb weakness.41,42 In addition, paresthesia of the distal limbs and ataxia may manifest.41,42 Approximately 50% of patients develop oropharyngeal weakness, and others may develop bilateral facial palsy, autonomic dysfunction (labile blood pressure and arrhythmia), and respiratory failure (20%).42,46
Individual reprints of this article and a bound reprint of the entire Symposium on Neurosciences will be available for purchase from our Web site www.mayoclinicproceedings.org.
The Symposium on Neurosciences will continue in an upcoming issue.